TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01041612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTFE Covered ComVi [full covered] Biliary Stent
Description: The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTFE Covered ComVi [full covered] Biliary Stent
Description: The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
Study: NCT00422006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy of muscle, of liver, and of adipose tissue
Description: biopsy of muscle, of liver, and of adipose tissue
Study: NCT01991379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
Study: NCT03411772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery will be conducted
Study: NCT01991379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
Study: NCT03941236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon analog
Study: NCT03676153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-provided guidance
Description: Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrative medicine treatment program
Description: Integrative medicine treatment program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine treatment program
Description: Integrative medicine treatment program
Study: NCT04802980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a vascular endothelial growth factor receptor decoy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a vascular endothelial growth factor receptor decoy
Study: NCT03679949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone, 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone, 2.5 mg
Study: NCT04802980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1T
Description: HB002.1T is a vascular endothelial growth factor receptor decoy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is an anti-tumor drug
Study: NCT00422006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy of muscle, of liver, and of adipose tissue
Description: biopsy of muscle, of liver, and of adipose tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy of muscle, of liver, and of adipose tissue
Description: biopsy of muscle, of liver, and of adipose tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy of muscle, of liver, and of adipose tissue
Description: biopsy of muscle, of liver, and of adipose tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamp euglycemic - hyperglycemic
Description: clamp euglycemic-hyperglycemic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamp euglycemic - hyperglycemic
Description: clamp euglycemic-hyperglycemic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamp euglycemic - hyperglycemic
Description: clamp euglycemic-hyperglycemic

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamp euglycemic - hyperglycemic
Description: clamp euglycemic-hyperglycemic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet
Study: NCT04802980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is an anti-tumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an anti-tumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is an anti-tumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an anti-tumor drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anti-tumor drug
Study: NCT01875367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injectable Solution
Description: Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injectable Solution
Description: Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
Study: NCT01875367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injectable Product
Description: Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injectable Product
Description: Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injection
Description: Powder for concentrate for solution for infusion. 1 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injection
Description: Powder for concentrate for solution for infusion. 1 cycle
Study: NCT02017236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: 600mg Volitinib ,single dose,oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volitinib
Description: 600mg Volitinib ,single dose,oral
Study: NCT02258867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection
Study: NCT00419276

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ambulatory continuous femoral nerve block for 100 hours
Description: Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
Study: NCT05231057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Mat, Pilates band or elastic bands, and Pilate's ball

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: pain relief, increasing flexibility, and mobility, improving muscle strength
Study: NCT02258867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: Solution for subcutaneous injection
Study: NCT02120157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy administration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Chemotherapy Administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unmanipulated Bone Marrow
Description: Bone Marrow Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressive Drug Administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressive Drug Administered
Study: NCT05231057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: pain relief, increasing flexibility, and mobility, improving muscle strength
Study: NCT03228433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 Capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 Capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 Capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-418
Description: TAK-418 Capsule.
Study: NCT03178812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS with fine-needle aspiration of pancreatic cyst
Description: EUS with fine-needle aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS with fine-needle aspiration of pancreatic cyst
Description: EUS with fine-needle aspiration

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Blood test
Description: Laboratory Blood Test
Study: NCT03354702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic
Description: Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
Study: NCT00441103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif® New Formulation (IFN-beta-1a, RNF)
Description: RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously three times a week for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebif® New Formulation (IFN-beta-1a, RNF)
Description: RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
Study: NCT04095754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head-Up Position
Description: Anti-Trendelenburg Position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head-Up Position
Description: Anti-Trendelenburg Position

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1

Intervention type: DRUG
Group type: OTHER
Intervention: Induction and maintenance of anaesthesia
Description: Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction and maintenance of anaesthesia
Description: Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim.
Study: NCT01059266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PURETHAL Grasses, 20.000 AUM/ml
Description: subcutaneous injections of increasing doses according to the described regimen
Study: NCT04095754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction and maintenance of anaesthesia
Description: Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim.
Study: NCT01309841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 12.5 mg oral tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet once daily
Study: NCT04597281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
Study: NCT00280150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Given 5 days a week for 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Given 5 days a week for 7 weeks
Study: NCT02900963

Intervention type: OTHER
Group type: OTHER
Intervention: weekly assessment of patient's weight
Description: Biological assessment to determine biological and inflammatory status Quality of life questionary
Study: NCT02782494

Intervention type: OTHER
Intervention: Examination of latent TB by QuantiFERON-TB
Description: Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
Study: NCT02996045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored \>4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.
Study: NCT01941940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
Study: NCT00492765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Description: dosage and frequency as per label

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta-1a
Description: dosage and frequency as per label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: dosage and frequency as per Biogen Idec protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage and frequency the same as simvastatin as per Biogen Idec Protocol
Study: NCT02993692

Intervention type: DEVICE
Group type: OTHER
Intervention: Direct laryngoscopy and fiberoptic bronchoscopy
Description: These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.

Intervention type: DEVICE
Group type: OTHER
Intervention: Direct laryngoscopy and fiberoptic bronchoscopy
Description: These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
Study: NCT00472121

Intervention type: DEVICE
Intervention: TOF-Watch SX (neuromuscular monitor)
Description: The variation between arms (dominant or non-dominant) when monitored with the same method on both arms

Intervention type: DEVICE
Intervention: TOF-Watch SX (neuromuscular monitor)
Description: The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
Study: NCT02287129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/m2
Study: NCT03679949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 1:0)
Description: Cannabis with high THC concentration and negligible CBD concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 1:0)
Description: Cannabis with high THC concentration and negligible CBD concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 0:1)
Description: Cannabis with high CBD concentration and negligible THC concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 0:1)
Description: Cannabis with high CBD concentration and negligible THC concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 1:1)
Description: Cannabis with equivalent CBD and THC concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC:CBD = ~ 1:1)
Description: Cannabis with equivalent CBD and THC concentrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Study: NCT00280150

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Given 5 days a week for 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Given 5 days a week for 7 weeks
Study: NCT01872091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy by immersion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Study: NCT04825119

Intervention type: DRUG
Intervention: Nusinersen
Description: Patients with SMA who will be treated with nusinersen will be included.
Study: NCT00422006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies for biological and genetic analyses
Description: biopsies for biological and genetic analyses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies for biological and genetic analyses
Description: biopsies for biological and genetic analyses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies for biological and genetic analyses
Description: biopsies for biological and genetic analyses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies for biological and genetic analyses
Description: biopsies for biological and genetic analyses
Study: NCT03832894

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Valerate
Description: Oestradiol supplementation starting from day of trigger through out the luteal phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate
Description: Oestradiol supplementation starting from day of trigger through out the luteal phase
Study: NCT04404166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PINGS 2
Description: Home BP monitoring, medication reminders using phone alerts, and patient education on hypertension, cardiovascular risk reduction \& stroke
Study: NCT03481608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lauric acid (coconut oil)
Description: A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Lauric acid (olive oil)
Description: A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.